Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

INSYS Therapeutics logo

About INSYS Therapeutics Stock (NASDAQ:INSY)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.23
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INSY Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.tc pixel
Aldeyra Therapeutics, Inc. (ALDX)
See More Headlines

INSY Stock Analysis - Frequently Asked Questions

INSYS Therapeutics, Inc. (NASDAQ:INSY) posted its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.33. The firm's revenue was down 68.1% compared to the same quarter last year.

INSYS Therapeutics shares split on Monday, March 31st 2014.The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were issued to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
5/10/2019
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
CIK
1516479
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.51 million
Net Margins
-346.61%
Pretax Margin
N/A
Return on Equity
-1,430.37%
Return on Assets
-64.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.54
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$82.08 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.58) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
74,570,000
Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:INSY) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners